Contextual Genomics’ Scientific Founders Recognized for their Exceptional Research Contributions

VANCOUVER, British Columbia–(BUSINESS WIRE)–#cancergenomics–Contextual Genomics Inc., a leading Canadian cancer genomics company
headquartered in Vancouver, Canada, announces that its Scientific
Founders, Drs. Samuel Aparicio, David Huntsman and Sohrab Shah, have
been recognized by Web of Science (Clarivate Analytics) for their
exceptional research performance, as determined by production of
multiple highly cited papers that rank in the top 1% by citations for
field and year. Of the world population of scientists and social
scientists, the Clarivate Analytics, Highly Cited Researchers are
one in 1,000.

The Clarivate Analytics list of Highly Cited Researchers for 2018
identifies scientists and social scientists who have demonstrated
significant influence through publication of multiple highly cited
papers during the last decade. Researchers are selected for their
exceptional performance in one or more of 21 fields or across several
fields.

Samuel Aparicio, Scientific Founder and Chief Scientific Officer of
Contextual Genomics, has been recognized in a new category this year –
cross field, recognizing those with outsized influence across several
fields. Dr. Aparicio’s research made significant contributions to a
number of Clarivate Analytics categories including clinical
medicine, molecular biology and genetics. “It is a privilege to be cited
in so many valuable publications across diverse fields,” said Dr.
Aparicio. “Our goal is to continue to help cancer patients around the
world, through academic discoveries, and through genomic assays
delivered by Contextual Genomics.”

Sohrab Shah, Scientific Founder and Chief Informatics Officer of
Contextual Genomics, has also been recognized in the new cross field
category. “Genome science requires cross-disciplinary collaboration –
computer scientists, statisticians, molecular biologists, geneticists
and pathologists. It’s exciting to see that our cross disciplinary
science is read and cited by our colleagues in the field,” said Dr.
Shah. “Contextual Genomics’ approach to helping patients has from the
very beginning brought together scientists across quantitative and
biomedical fields working in an integrated environment to deliver
comprehensive molecular and informatics solutions.”

David Huntsman, Scientific Founder and Chief Medical Officer of
Contextual Genomics, has been recognized in the field of Clinical
Medicine. “This acknowledgment means that our academic research has
effectively influenced the research of other scientists around the
world,” says Dr. Huntsman. “Contextual Genomics has enabled us to use
cancer genomics to impact patients directly around the world.”

In 2012, Drs. Aparicio, Shah and Huntsman founded Contextual Genomics,
partner of choice to help clinical laboratories implement quality
assured Next Generation Sequence (NGS) based somatic mutation testing in
their own facilities. Contextual Genomics’ solutions allow partner
laboratories to facilitate access for cancer patients to high quality
and affordable genomic testing for improved cancer care through a more
personalized and targeted therapy approach. “That the three Scientific
Founders of Contextual Genomics, all of which are Canada Research
Chairs, are recognized through the impact of their work on other
research speaks to the high level of the science that underpins all of
Contextual Genomics’ activities and may mark us as unique in our
sector,” said Celia Courchene, President of Contextual Genomics.

Contextual Genomics has developed FIND ITTM, a proprietary
molecular hotspot assay that screens for more than 140 somatic genome
alterations found in solid tumour cancers to identify optimal
therapeutic treatments and recognize acquired drug resistant mutations,
making it possible for doctors to customize therapies with greater
precision for cancer patients. The FIND ITTM assay, supported
by Contextual Genomics’ innovative, cloud-based analysis engine, also
helps to determine prognostic and diagnostic implications for patient
care.

Contextual Genomics is also developing FOLLOW ITTM, a
proprietary mutation detection liquid biopsy assay that screens for
cell-free circulating tumour DNA (ctDNA) in plasma. FOLLOW ITTM
will be deployed for patients with widespread metastatic disease at
diagnosis and for use as a time series monitoring tool to read out
tumour burden and treatment resistance. FOLLOW ITTM will
screen for all of the same somatic genome alterations as FIND ITTM
and can be used to follow disease progression for patients, including
those whose tumours were initially tested with FIND ITTM.

Chris Wagner, Contextual Genomics’ Executive Chairman, said “This
external validation of the work of Drs. Aparicio, Shah and Huntsman is
well deserved. We see the important contributions these dedicated
scientists make through the scientific, informatics and medical
leadership that they provide to our team, products and business every
day and we are very happy to see it recognized in such a prestigious
way. Their exceptional leadership, combined with the talents of our
team, have allowed us to develop and deliver our very important
products, including FIND ITTM and FOLLOW ITTM, for
the worldwide cancer community.”

About Contextual’s Products:

The FIND ITTM and FOLLOW ITTM cancer panels are
multiplex, next- generation sequencing genomic assays designed for rapid
deployment into labs around the world. Both FIND ITTM and
FOLLOW ITTM evaluate the mutation status of tumour DNA (FIND
ITTM for solid tumours; FOLLOW ITTM for cell-free
circulating tumour DNA in plasma) at 140 well-characterized positions,
identifying the somatic mutations that have the greatest potential to
impact treatment decisions. QUALITY NEXUSTM is a quality
control system embedded into all FIND ITTM and FOLLOW ITTM
assays and into Contextual Genomics’ cloud-based analysis engine. FIND ITTM
and FOLLOW ITTM physician reports provide clear information
on test interpretation and linkages to current therapeutic options.

About Contextual Genomics (www.contextualgenomics.com):

Contextual Genomics develops cost-effective and clinically actionable
molecular tests that guide diagnosis and treatment of cancer. These
customized tests are offered by our partner laboratories around the
world with Contextual conducting cloud-based bioinformatics services via
a SaaS model. The collection of data via this robust network of partners
and the use of machine-learning tools allows Contextual Genomics to
improve patient care through improved clinical trial enrolment and new
treatment algorithms. Contextual Genomics is founded and managed by
global leaders in cancer medicine and bioinformatics, who have
unparalleled expertise in cancer genomics and the clonal evolution of
cancer.

This release contains forward-looking statements that are not based
on historical fact. These forward-looking statements involve risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from those expressed
or implied by such forward-looking statements. Readers are cautioned not
to place undue reliance on such forward-looking statements.

Contacts

Contextual Genomics Media Contact
Email: media@contextualgenomics.com